Cargando…

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life

BACKGROUND: Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration. OBJECTIVE: The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral do...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlender, Jan-Frederik, Teutonico, Donato, Coboeken, Katrin, Schnizler, Katrin, Eissing, Thomas, Willmann, Stefan, Jaehde, Ulrich, Stass, Heino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267540/
https://www.ncbi.nlm.nih.gov/pubmed/29737457
http://dx.doi.org/10.1007/s40262-018-0661-6
_version_ 1783376098222931968
author Schlender, Jan-Frederik
Teutonico, Donato
Coboeken, Katrin
Schnizler, Katrin
Eissing, Thomas
Willmann, Stefan
Jaehde, Ulrich
Stass, Heino
author_facet Schlender, Jan-Frederik
Teutonico, Donato
Coboeken, Katrin
Schnizler, Katrin
Eissing, Thomas
Willmann, Stefan
Jaehde, Ulrich
Stass, Heino
author_sort Schlender, Jan-Frederik
collection PubMed
description BACKGROUND: Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration. OBJECTIVE: The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral dosing based on a comprehensive literature review, and evaluate the predictive performance towards pediatric and geriatric patients. METHODS: The aim of this report was to establish confidence in simulations of the ciprofloxacin PBPK model along the development process to facilitate reliable predictions outside of the tested adult age range towards the extremes of ages. Therefore, mean data of 69 published clinical trials were identified and integrated into the model building, simulation and verification process. The predictive performance on both ends of the age scale was assessed using individual data of 258 subjects observed in own clinical trials. RESULTS: Ciprofloxacin model verification demonstrated no concentration-related bias and accurate simulations for the adult age range, with only 4.8% of the mean observed data points for intravenous administration and 12.1% for oral administration being outside the simulated twofold range. Predictions towards the extremes of ages for the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration (C(max)) over the entire span of life revealed a reliable estimation, with only two pediatric AUC observations outside the 90% prediction interval. CONCLUSION: Overall, this ciprofloxacin PBPK modeling approach demonstrated the predictive power of a thoroughly informed middle-out approach towards age groups of interest to potentially support the decision-making process. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40262-018-0661-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6267540
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-62675402018-12-11 A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life Schlender, Jan-Frederik Teutonico, Donato Coboeken, Katrin Schnizler, Katrin Eissing, Thomas Willmann, Stefan Jaehde, Ulrich Stass, Heino Clin Pharmacokinet Original Research Article BACKGROUND: Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration. OBJECTIVE: The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral dosing based on a comprehensive literature review, and evaluate the predictive performance towards pediatric and geriatric patients. METHODS: The aim of this report was to establish confidence in simulations of the ciprofloxacin PBPK model along the development process to facilitate reliable predictions outside of the tested adult age range towards the extremes of ages. Therefore, mean data of 69 published clinical trials were identified and integrated into the model building, simulation and verification process. The predictive performance on both ends of the age scale was assessed using individual data of 258 subjects observed in own clinical trials. RESULTS: Ciprofloxacin model verification demonstrated no concentration-related bias and accurate simulations for the adult age range, with only 4.8% of the mean observed data points for intravenous administration and 12.1% for oral administration being outside the simulated twofold range. Predictions towards the extremes of ages for the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration (C(max)) over the entire span of life revealed a reliable estimation, with only two pediatric AUC observations outside the 90% prediction interval. CONCLUSION: Overall, this ciprofloxacin PBPK modeling approach demonstrated the predictive power of a thoroughly informed middle-out approach towards age groups of interest to potentially support the decision-making process. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40262-018-0661-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-05-08 2018 /pmc/articles/PMC6267540/ /pubmed/29737457 http://dx.doi.org/10.1007/s40262-018-0661-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Schlender, Jan-Frederik
Teutonico, Donato
Coboeken, Katrin
Schnizler, Katrin
Eissing, Thomas
Willmann, Stefan
Jaehde, Ulrich
Stass, Heino
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
title A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
title_full A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
title_fullStr A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
title_full_unstemmed A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
title_short A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
title_sort physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267540/
https://www.ncbi.nlm.nih.gov/pubmed/29737457
http://dx.doi.org/10.1007/s40262-018-0661-6
work_keys_str_mv AT schlenderjanfrederik aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT teutonicodonato aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT coboekenkatrin aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT schnizlerkatrin aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT eissingthomas aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT willmannstefan aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT jaehdeulrich aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT stassheino aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT schlenderjanfrederik physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT teutonicodonato physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT coboekenkatrin physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT schnizlerkatrin physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT eissingthomas physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT willmannstefan physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT jaehdeulrich physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife
AT stassheino physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife